Pharmacoepidemiol Drug Saf 2007;16(10):1111-9
While Novo Nordisk maintains dominance through scale and innovation, Boehringer Ingelheim is demonstrating significant growth potential
The Biology Problem: Why Many GLP-1 Users Quit or Dont Respond While GLP-1 medications such as Wegovy, Ozempic, and Zepbound have reshaped metabolic health, real-world outcomes remain inconsistent: 3040% of users experience significant GI-related adverse effects Many experience hair loss, muscle loss, constipation, and nutrient deficiencies Nearly 25% lose less than 5% of their body weight, driven by insulin resistance, impaired glucose control, or microbiome-mediated variability in drug response
doi:10.3389/fnagi.2019.00257 Pillai JB, Isbatan A, Imai SI, Gupta MP